Abstract: A composition comprising a compound of formula (I) or (II): wherein r and q are independently integers of 1 to 3; Rf is linear or branched chain perfluoroalkyl group having 1 to 6 carbon atoms; j is an integer 0 or 1, or a mixture thereof, x is 1 or 2, Z is —O— or —S—, X is hydrogen or M, and M is an ammonium ion, an alkali metal ion, or an alkanolammonium ion is disclosed.

Abstract: A composition includes a salt of a carboxyethyl phosphinate ester compound. Additionally, the composition may also include a polymeric resin, such as a thermoplastic resin. The composition may have improved physical and chemical properties including flame retardancy, thermal stability, and hygroscopicity.

Abstract: Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing neuronal cell death-related diseases or conditions in a human or a non-human animal.

Abstract: A process is described for the production of one or more of linear nitriles, amides and formamides which includes reacting a nitrogen containing compound, such as ammonia or NOx, and a synthesis gas over a catalyst at a temperature of between 160° C. and 400° C. and a pressure of between 1 bar and 50 bar. A further process for the production of one or more of linear phosphorous containing compounds is also described, which includes reacting a phosphorous containing compound, such as a phosphine, and a synthesis gas over a catalyst at a temperature of between 160° C. and 400° C. and a pressure of between 1 bar and 50 bar. A supported cobalt, iron, ruthenium or rhodium catalyst or an unsupported (bulk) promoted iron catalyst, modified with a promoter is used. The synthesis gas is a mixture of hydrogen and carbon monoxide, in a ratio from 0.5:1 to 5:1; or a mixture of hydrogen and carbon dioxide; or a mixture of water and carbon monoxide.

Abstract: The present invention describes novel compounds and methods for capping reactive groups on support and during multistep synthesis. These new capping reagents are also useful for high quality synthesis on solid supports and surfaces used as microarrays, biosensors, or in general as biochips. The compounds are also useful for controlling surface density of reactive groups on a support. The compounds may also be used to modify the hydrophilic/hydrophobic characteristics of a surface or a molecule. The compounds have functional utility in various applications in the fields of genomics, proteomics, diagnostics and medicine.

Abstract: A process for producing a biarylphosphine compound is disclosed. The process has a step of subjecting a biarylsulfonate compound to coupling reaction with a hydrogen-phosphine compound in the presence of a catalyst and an organic strong base to obtain a biarylphosphine compound. As the catalyst, preferably used is a nickel compound or a palladium compound. As the organic strong base, preferably used is 1,8-diazabicyclo[5.4.0]undecene-7 (DBU).

Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

Abstract: Dental composition containing (i) at least one acid (meth)acrylamide monomer which has two or more polymerizable groups, (ii) at least one acid monomer which has only one polymerizable group and (iii) at least one polymerization initiator.

Abstract: Methods of separating actinides from lanthanides are disclosed. A regio-specific/stereo-specific dithiophosphinic acid having organic moieties is provided in an organic solvent that is then contacted with an acidic medium containing an actinide and a lanthanide. The method can extend to separating actinides from one another. Actinides are extracted as a complex with the dithiophosphinic acid. Separation compositions include an aqueous phase, an organic phase, dithiophosphinic acid, and at least one actinide. The compositions may include additional actinides and/or lanthanides. A method of producing a dithiophosphinic acid comprising at least two organic moieties selected from aromatics and alkyls, each moiety having at least one functional group is also disclosed. A source of sulfur is reacted with a halophosphine. An ammonium salt of the dithiophosphinic acid product is precipitated out of the reaction mixture. The precipitated salt is dissolved in ether.

Abstract: The invention relates to carboxylic acid derivates which contain at least one organically polymerisable group and at least one group which contains phosphorous and is reactive or that modulates the properties of the molecule. The invention also relates to a method for production of the inventive molecules and the use thereof in dentistry and for influencing the properties of materials.

Abstract: A subject-matter of the invention is alkoxyamines resulting from ?-phosphorated nitroxides corresponding to the formula: in which R represents an alkyl radical having a number of carbon atoms ranging from 1 to 3, R1 represents a hydrogen atom or a residue: in which R3 represents an alkyl radical having a number of carbon atoms ranging from 1 to 20, and R2 represents a hydrogen atom, an alkyl radical having a number of carbon atoms ranging from 1 to 8, a phenyl radical, an alkali metal, such as Li, Na or K, H4N+, Bu4N+ or Bu3HN+, exhibiting a kinetic dissociation constant kd, measured at 120° C. by EPR, of greater than 0.05 s?1. These compounds can be used as initiators for the (co)polymerizations of at least one monomer which can be polymerized by the radical route.

Abstract: The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain hydrophilic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. The polymeric compositions comprise polymerizable hydrophilic siloxanyl monomers.

Abstract: The invention relates to a phosphonium borate compound represented by Formula (I) (hereinafter, the compound (I)). The invention has objects of providing (A) a novel process whereby the compound is produced safely on an industrial scale, by simple reaction operations and in a high yield; (B) a novel compound that is easily handled; and (C) novel use as catalyst. Formula (I): (R1)(R2)(R3)PH.BAr4??(I) wherein R1, R2, R3 and Ar are as defined in the specification. The process (A) includes reacting a phosphine with a) HCl or b) H2SO4 to produce a) a hydrochloride or b) a sulfate; and reacting the salt with a tetraarylborate compound. The compound (B) has for example a secondary or tertiary alkyl group as R1 and is easily handled in air without special attention.

Abstract: Phosphine triazole ligand compounds, prepared through click chemistry, complex with transition metals to form transition metal-phosphine triazole ligand complexes. These complexes are useful catalysts in coupling reactions such as Suzuki-Miyaura coupling, Stille coupling, Negishi coupling, Sonagashira coupling, carbon-heteroatom bond-forming reactions (C—O and C—N), alpha alkylation of carbonyls, Heck coupling reactions, and hydrogenation reactions.

Abstract: A process is provided for reacting dichloromonophenyl phosphate and monochlorodiphenyl phosphate with aliphatic alcohol in the presence of a Lewis acid catalyst and absence of solvent, at a temperature above 60 to 200° C. and pressure of 0.001 to 1.1 bara, and sparging the reaction mixture with an inert carrier gas if the pressure is above 0.67 bars. Mixtures of monoalkyl biphenyl phosphates and dialkyl monophenyl phosphates and use of such mixtures as a plasticizer and/or flame retardant, are also provided.

Abstract: The invention concerns a process for preparing a hybrid organic-inorganic material (HOIM) with phosphorus-containing bridges between the surface of an inorganic substrate containing an element M and one or more organic groups of the covalent M-O-P-R type, said process using, as a precursor for said organic group or groups, at least one organophosphorus acid halide with formula RxP(O)Xy in which x=1 or 2, y=3?x, X being a halogen and R designating at least one organic alkyl, aryl or aryl-alkyl group. Non-exhaustive applications for the hybrid organic-inorganic material obtained by the process of the invention are in the fields of anti-corrosion, lubrication, microelectronics, nanotechnologies, composite materials, heterogeneous catalysis, supported catalysis, depollution and biomedical applications.

Abstract: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters of phosphonates.

Abstract: The present invention relates to a process for the preparation of perfluoroalkylphosphines comprising at least the reaction of at least one fluoro(perfluoroalkyl)phosphorane with at least one hydride ion donor, and to the use of tris(perfluoroalkyl)phosphines as perfluoroalkylating reagents.

Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: The invention relates to a method for the continuous production of aldehydes by the isomerising hydroformylation in a homogenous phase of olefin compositions by means of a synthesis gas, in the presence of a homogeneous rhodium catalyst that is complexed with an organophosphorus ligand containing oxygen atoms and/or nitrogen atoms and a free ligand. The production is carried out at high temperature and high pressure in a multi-stage reaction system consisting of at least two reaction zones. According to the method, the olefin composition is first reacted in a first reaction zone or a group of several first reaction zones at a total pressure of between 10 and 40 bar, using a synthesis gas with a CO/H2 molar ratio of between 4:1 and 1:2 until a 40 to 95% conversion of the ?-olefins is obtained.

Abstract: A non-aqueous electrolyte cell comprises a positive electrode, a negative electrode and a non-aqueous electrolyte containing a support salt. The non-aqueous electrolyte further comprises a phosphazene derivative. The phosphazene derivative having a specified structure functions as an electrode stabilizing agent or a non-combustion agent.

Abstract: The present invention relates to compositions comprising a water-insoluble pharmaceutically active ingredient or a substance having low water solubility, and a compound represented by Structural Formula (I): in which A is: The present invention further relates to methods of solubilizing substances of low water solubility, and methods of preparing compositions suitable for intravenous administration.

Abstract: The invention relates to a novel process for conditioning isocyanates. The purpose of conditioning of isocyanates or of mixtures of isocyanates is to remove organophosphorus components in a suitable manner such that the organophosphorus compounds no longer interfere with processing of the isocyanates.

Abstract: A composition comprising a mixture, having a maximum molar ratio of acid to base of 0.6 and providing water repellency when applied to a substrate surface without etching of said surface, of A) an anionic aqueous fluoroalkyl phosphate solution which provides at least about 75% of the total fluorine content of said composition, and B) a cationic copolymer of fluoroalkyl(meth)acrylate or perfluoroalkylether(meth)acrylate present at a minimum of 0.3 g per 100 g of said composition.

Abstract: The present invention provides compositions (small molecules, oligomers and polymers) that can be used to modify charge transport across a nanocrystal surface or within a nanocrystal-containing matrix, as well as methods for making and using the novel compositions.

Abstract: The present invention provides polymeric compositions that can be used to modify charge transport across a nanocrystal surface or within a nanocrystal-containing matrix, as well as methods for making and using the novel compositions.

Abstract: A process for extraction and recovery of phosphorus from solid animal wastes such as for example, poultry litter waste, includes the steps of phosphorus extraction, phosphorus recovery, and phosphorus recovery enhancement. The process can be performed in batch or continuous mode.

Abstract: A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom, or an alkyl group, R2 represents a hydroxyalkyl group, or a triarylmethyloxyalkyl group, or R1 and R2 combine together to represent —C(R3)(R4)— (R3 and R4 represent hydrogen atom, an alkyl group, or hydroxyl group, or R3 and R4 may combine together to represent oxo group), or —C(R5)(R6)—O—C(R7)(R8)— (R5 to R8 represent hydrogen atom, an alkyl group, or hydroxyl group, or R5 and R6 may combine together to represent oxo group, and R7 and R8 may combine together to represent oxo group); Ar1 to Ar4 independently represent an aryl group (the aryl group may have 1 to 5 of the same or different substituents), *1 to *4 indicate asymmetric carbons, and configurations are cis between *1 and *2, cis between *3 and *4, and trans between *2 and *3]. An optically active phosphine ligand which can be easily synthesized and gives a transition metal complex showing superior asymmetric catalyst activity is provided.

Abstract: The present invention provides BZPA products with improved flowability and two methods of producing such BZPA products. Both methods successfully produce BZPA products that are not prone to agglomerate upon storage, and thus the flowability of such BZPA products does not degrade over time. The first method includes mechanically forming the BZPA crystals into large compacted pellets or briquettes without the introduction of any additives or binders. The compacted pellets are large enough that the physical and chemical effects that occur on the surface of small crystal particles are eliminated or minimized, but small enough that the BZPA can be easily handled and used in commercial applications. The second method includes adding a substantially inert anti-caking agent to the BZPA crystals to minimize or retard their tendency to agglomerate. The preferred anti-caking agent is silicon dioxide (SiO2), which is blended with the BZPA crystals in small amounts.

Abstract: One embodiment of the present invention relates to ionic liquids and ionic viscoelastics formed between [1] a small molecule or macromolecule containing two or more cations; and [2] a small molecule or macromolecule containing two or more anions. Another embodiment of the invention is the use of the inventive ionic liquids and ionic viscoelastics, formed between a small molecule or macromolecule containing two or more cations and a small molecule or macromolecule containing two or more anions, to form a crosslinked network. In certain embodiments, the ionic liquids formed can be viscous liquids, viscous liquid formed networks, or viscoelastic networks/gels. In certain embodiments, the ionic material of the invention may be used for a variety of applications including, but not limited to, lubricants, additives, gas separation, liquid separation, membranes, fuel cells, sensors, batteries, coatings, heat storage, liquid crystals, biocompatible fluids, solvents, and electronic materials.

Abstract: Disclosed is a process for the recovery of phosphorus and/or iodine containing catalyst components, present as an organophosphorus compound such as trihydrocarbylphosphine compounds and tetrahydrocarbylphosphonium compounds, from a solution of at least one such organophosphorus compound in an organic solvent by the steps comprising (1) converting the organophosphorus compound to an iodide complex of a organophosphonium compound which is insoluble in the organic solvent; and (2) separating the insoluble iodide complex of the organophosphonium compound from the solution. The process also results in the recovery of iodine values present in the solution.

Abstract: Materials and Methods for preparing (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid and structurally related compounds via enantioselective hydrogenation of prochiral olefins are disclosed. The methods employ novel chiral catalysts, which include C1-symmetric bisphosphine ligands bound to transition metals.

Abstract: Tetraphosphorous ligands are combined with transition metal salts to form catalysts for use in hydroformylation, isomerization-hydroformylation, hydrocarboxylation, hydrocyan-ation, isomerization-formylation, hydroaminomethylation and similar related reactions.

Abstract: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

Abstract: A process for producing a biarylphosphine compound is disclosed. The process has a step of subjecting a biarylsulfonate compound to coupling reaction with a hydrogen-phosphine compound in the presence of a catalyst and an organic strong base to obtain a biarylphosphine compound. As the catalyst, preferably used is a nickel compound or a palladium compound. As the organic strong base, preferably used is 1,8-diazabicyclo[5.4.0]undecene-7 (DBU).

Abstract: This invention provides a method for generating secondary phosphines from secondary phosphine oxides in the presence of a reducing agent, such as diisobutylaluminum hydride (DIBAL-H), triisobutyldialuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, or another reducing agent comprising: (i) an R1R2AlH moiety, wherein R1 and R2 are each an alkyl species or oxygen, and wherein at least one of R1 or R2 comprises at least 2 carbon atoms, or (ii) an R1R2R3Al moiety, wherein R1, R2, and R3 are not hydrogen, and wherein at least one of R1, R2, and R3 is an alkyl species comprising a ?-hydrogen, not including triethylaluminum. Preferred reducing agents for the present invention include: diisobutylaluminum hydride, triisobutyldialiuminoxane, triisobutylaluminum, tetraisobutyldialuminoxane, and combinations thereof.

Abstract: A novel transition metal complex, preferably a ruthenium-phosphine complex or rhodium-phosphine complex, which is effectively usable in various asymmetric syntheses and, in particular, is more effectively usable in the asymmetric hydrogenation of various ketones; and a novel process for producing an optically active alcohol with the complex. The novel transition metal complex includes a ligand obtained by introducing a diarylphosphino group into each of the 2- and 2?-positions of diphenyl ether, benzophenone, benzhydrol, or the like. It preferably further includes an optically active 1,2-diphenylethylenediamine coordinated thereto. The complex preferably is a novel diphosphine-ruthenium-optically active diamine complex or diphosphine-rhodium-optically active diamine complex. The process comprises using the complex as an asymmetric hydrogenation catalyst to conduct the asymmetric hydrogenation of a ketone compound to thereby obtain an optically active alcohol in a high optical purity and a high yield.

Abstract: The invention relates to a curing accelerator for a curing resin obtained by reacting a phosphine compound (a) with a compound (b) having at least one halogen atom substituted on an aromatic ring and at least one proton atom which can be discharged, and subjecting the reaction product to dehydrohalogenation, a curing resin composition containing the curing accelerator, and an electronic component device having a device component encapsulated with the curing resin composition. The curing accelerator exhibits superior curability under moisture absorption, flow properties, reflow cracking resistance and high-temperature storage characteristics.

Abstract: A process for the preparation of bis-acylphosphanes of formula R1P(COR2)2 wherein R1 is unsubstituted phenyl or phenyl substituted by one to five halogen, C1-C8-alkyl, C1-C8-alkylthio and/or C1-C8-alkoxy; R2 is C1-C18-alkyl or C2-C18-alkenyl; C1-C18-alkyl or C2-C18-alkenyl substituted once or more than once by halogen —OR10, —OCO—R10, —OCO-Hal, —COO—R10, —N(R11)—CO—R10, —N(R11)—CO-Hal, —CO—NR11R10, —CH?CH—CO—OR10 or —CH?CH-phenyl; —C(C1-C4alkyl)=C(C1-C4alkyl)-CO—OR10 or —C(C1-C4alkyl)=C(C1-C4alkyl)-phenyl; C5-C12cycloalkyl, C2-C18alkenyl, phenyl-C1-C4alkenyl, phenyl, naphthyl, biphenyl or a 5- or 6-membered —O—, S— or N-containing heterocyclic ring, the radicals phenyl, naphthyl, biphenyl or the 5- or 6-membered -0-, S— or N-containing heterocyclic ring being unsubstituted or substituted by one to five halogen, C1-C8alkyl, C1-C8alkoxy and/or C1-C8alkylthio; the process comprises the steps in a) selective reduction of dichlorophenylphosphanes of the formula R1P(CI)2 by means of hydrogen at a temperature in the

Abstract: A composition comprising a compound of formula (I) or (II): wherein r and q are independently integers of 1 to 3; Rf is linear or branched chain perfluoroalkyl group having 1 to 6 carbon atoms; j is an integer 0 or 1, or a mixture thereof, x is 1 or 2, Z is —O— or —S—, X is hydrogen or M, and M is an ammonium ion, an alkali metal ion, or an alkanolammonium ion is disclosed.

Abstract: Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.

Abstract: The present invention concerns novel bidentante optionally N-containing P-ligands of general Formula (I) embracing a two-ring-system and processes for synthesizing them, transition metal complexes of these compounds and their use as catalysts.

Abstract: The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as dopants in the emitting layer.

Abstract: Non-C2-symmetric bisphospholane ligands and methods for their preparation are described. Use of metal/non-C2-symmetric bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.

Abstract: This invention relates to surfactant compositions comprising a phosphate fluorosurfactant and a siloxane surfactant wherein the surfactant composition's ability to lower equilibrium surface tension exceeds that of either the phosphate fluorosurfactant or the siloxane surfactant. Because of the synergistic interaction of the phosphate fluorosurfactant and the siloxane surfactant, it is possible to use only small amounts of the more expensive fluorosurfactant in the surfactant composition of the present invention while preserving or improving the ability to lower the equilibrium surface tension of a liquid, such as water.

Abstract: Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described: and pharmaceutically acceptable prodrugs and salts thereof.

Abstract: A process for the minimization of phosphonium ion ligand degradation products formed during reaction of a polyunsaturated olefin or an unconjugated functionalized olefin in the presence of a transition metal-triorganophosphine ligand complex catalyst to form as a product, by-product, or intermediate product a conjugated functionalized olefin having a carbon-carbon double bond conjugated to an a-electronwithdrawing group, such as, an a,?-unsaturated aldehyde, ketone, ester, acid, or nitrile. The minimization process involves conducting the reaction under selected conditions of conversion, temperature, pressure, or a combination thereof; and/or by selecting a triorganophosphine ligand with a specified steric and/or electronic property.

Abstract: Ligand synthesis methods for the preparation of ligands having the formula wherein Q is selected from phosphorus, arsenic and antimony; wherein X1, X2 and X3 are carbon anions; and, wherein R15 is selected from —SO3, —SO2N(R18), —CO2, —PO3, —AsO3, —SiO2, —C(CF3)2O; where R18 is selected from a hydrogen, a halogen, a hydrocarbyl group and a substituted hydrocarbyl group, are disclosed. Also disclosed are methods of complexing the ligands with late transition metals to form catalyst complexes that catalyze polymerization reactions and/or Heck coupling reactions.

Abstract: The invention relates to intermediate compounds of the formula wherein R1 is H or a protecting group, R2 and R3 each independently represent H, methyl, or a leaving group, provided that at least one, but not both, of R2 and R3 is a leaving group. The intermediate compounds are useful for the synthesis of discodermolide, its derivatives, and related compounds.

Abstract: Unsaturated alkyllysophosphonocholines compounds of formula (I) or (II): or pharmaceutically-acceptable salts, prodrugs or isomers thereof. The compounds of the invention have anti-neoplastic activity, and accordingly have utility in treating cancer and related diseases. The invention also provides enantiomers of these compounds, as well as synthetic methods for producing an enantiomer, substantially free of the other enantiomer. Also disclosed are pharmaceutical compositions, as well methods for treating cancer with the pharmaceutical compositions.